Loading...
13 ibuprofen COVID-19 controlled studies, 1 RCTs
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Rinott -21% 1.21 [0.33-4.38] death 3/87 9/316 Improvement, RR [CI] Treatment Control Rinott -12% 1.12 [0.37-3.34] ventilation 4/87 13/316 Rinott -40% 1.40 [0.51-3.81] ICU 5/87 13/316 Abu Esba -170% 2.70 [0.33-22.0] death 1/40 11/357 Abu Esba 37% 0.63 [0.07-5.44] death 40 (n) 357 (n) Abu Esba -45% 1.45 [0.44-4.81] oxygen 40 (n) 357 (n) Abu Esba -18% 1.18 [0.59-2.36] hosp. 40 (n) 357 (n) Abu Esba -85% 1.85 [0.42-8.13] severe case 40 (n) 357 (n) Sobhy (DB RCT) 52% 0.48 [0.24-0.95] ICU 10/90 21/90 OT1 Sobhy (DB RCT) 52% 0.48 [0.24-0.95] oxygen 10/90 21/90 OT1 Sobhy (DB RCT) 26% 0.74 [0.58-0.94] hosp. time 90 (n) 90 (n) OT1 Sobhy (DB RCT) 25% 0.75 [0.17-3.26] no recov. 3/90 4/90 OT1 Sobhy (DB RCT) 43% 0.57 [0.25-1.29] no recov. 8/90 14/90 OT1 Sobhy (DB RCT) 48% 0.52 [0.28-0.95] no recov. 13/90 25/90 OT1 Sobhy (DB RCT) 41% 0.59 [0.37-0.94] no recov. 20/90 34/90 OT1 Choi (PSM) -240% 3.40 [0.64-18.1] progression case control Samimagham -100% 2.00 [1.33-3.02] death 63 (n) 95 (n) Samimagham -428% 5.28 [1.82-15.3] severe case 14/63 4/95 Samimagham -13% 1.13 [1.02-1.25] progression 60/63 80/95 Kragholm 4% 0.96 [0.72-1.23] progression 264 (n) 3,738 (n) Wong -23% 1.23 [0.90-1.68] death population-based cohort Wong 17% 0.83 [0.56-1.25] death population-based cohort Reese (PSM) 9% 0.91 [0.62-1.35] death 5,737 (n) 5,737 (n) Reese (PSM) -303% 4.03 [3.69-4.40] severe case 5,737 (n) 5,737 (n) Drake 10% 0.90 [0.71-1.13] death n/a n/a Leal 3% 0.97 [0.94-1.00] cases n/a n/a Campbell (PSW) 0% 1.00 [0.99-1.01] death 1,814 (n) 20,311 (n) Campbell (PSW) 1% 0.99 [0.98-1.00] death 1,814 (n) 20,311 (n) Xie -12% 1.12 [0.92-1.38] hosp. population-based cohort OT1 Xie -8% 1.08 [0.95-1.22] cases population-based cohort OT1 Loucera 48% 0.52 [0.34-0.78] death 519 (n) 15,449 (n) Ibuprofen COVID-19 outcomes c19 earlyApril 2024 1 OT: comparison with other treatment Favors ibuprofen Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
